These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23876164)

  • 1. Uveitis risk following oral fluoroquinolone therapy: a nested case-control Study.
    Forooghian F; Maberley D; Albiani DA; Kirker AW; Merkur AB; Etminan M
    Ocul Immunol Inflamm; 2013 Oct; 21(5):390-3. PubMed ID: 23876164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral Fluoroquinolones and the Risk of Uveitis.
    Sandhu HS; Brucker AJ; Ma L; VanderBeek BL
    JAMA Ophthalmol; 2016 Jan; 134(1):38-43. PubMed ID: 26512796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral fluoroquinolones and the risk of retinal detachment.
    Etminan M; Forooghian F; Brophy JM; Bird ST; Maberley D
    JAMA; 2012 Apr; 307(13):1414-9. PubMed ID: 22474205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilateral uveitis associated with fluoroquinolone therapy.
    Hinkle DM; Dacey MS; Mandelcorn E; Kalyani P; Mauro J; Bates JH; Soukasian SH; Holland GN; Foster CS; Fraunfelder FT; Davis JL; Fraunfelder FW
    Cutan Ocul Toxicol; 2012 Jun; 31(2):111-6. PubMed ID: 21981449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between oral fluoroquinolones and retinal detachment.
    Albini TA; Karakousis PC; Abbey AM; Bartlett JG; Flynn HW
    Am J Ophthalmol; 2012 Dec; 154(6):919-921.e1. PubMed ID: 23149367
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk for uveitis with oral moxifloxacin: a comparative safety study.
    Eadie B; Etminan M; Mikelberg FS
    JAMA Ophthalmol; 2015 Jan; 133(1):81-4. PubMed ID: 25275293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated diarrhea.
    Novell MJ; Morreale CA
    Ann Pharmacother; 2010 May; 44(5):826-31. PubMed ID: 20354161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between oral fluoroquinolone use and retinal detachment.
    Pasternak B; Svanström H; Melbye M; Hviid A
    JAMA; 2013 Nov; 310(20):2184-90. PubMed ID: 24281462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population.
    Seeger JD; West WA; Fife D; Noel GJ; Johnson LN; Walker AM
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):784-92. PubMed ID: 16456878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral fluoroquinolones and risk of glaucoma.
    Yang L; Etminan M; Mikelberg FS
    J Glaucoma; 2014 Sep; 23(7):464-6. PubMed ID: 23632400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study.
    Sodhi M; Sheldon CA; Carleton B; Etminan M
    Neurology; 2017 Aug; 89(8):792-795. PubMed ID: 28754842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Fluoroquinolone Use and Risk of Uveitis or Retinal Detachment.
    Brown JP; Wing K; Evans SJ; Leyrat C; Mansfield KE; Smeeth L; Wong AYS; Yorston D; Galwey NW; Douglas IJ
    JAMA Ophthalmol; 2024 Jul; 142(7):636-645. PubMed ID: 38814618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of gastrointestinal perforation in patients taking oral fluoroquinolone therapy: An analysis of nationally representative cohort.
    Hsu SC; Chang SS; Lee MG; Lee SH; Tsai YW; Lin SC; Chen ST; Weng YC; Porta L; Wu JY; Lee CC
    PLoS One; 2017; 12(9):e0183813. PubMed ID: 28873440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outpatient gatifloxacin therapy and dysglycemia in older adults.
    Park-Wyllie LY; Juurlink DN; Kopp A; Shah BR; Stukel TA; Stumpo C; Dresser L; Low DE; Mamdani MM
    N Engl J Med; 2006 Mar; 354(13):1352-61. PubMed ID: 16510739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions.
    Lee EY; Gomes T; Drucker AM; Daneman N; Asaf A; Wu F; Piguet V; Juurlink DN
    JAMA; 2024 Sep; 332(9):730-737. PubMed ID: 39115856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diplopia and fluoroquinolones.
    Fraunfelder FW; Fraunfelder FT
    Ophthalmology; 2009 Sep; 116(9):1814-7. PubMed ID: 19643481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Oral Fluoroquinolone Use and Retinal Detachment.
    Raguideau F; Lemaitre M; Dray-Spira R; Zureik M
    JAMA Ophthalmol; 2016 Apr; 134(4):415-21. PubMed ID: 26967005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of risk factors for malignant Mediterranean spotted fever indicates that fluoroquinolone treatment has a deleterious effect.
    Botelho-Nevers E; Rovery C; Richet H; Raoult D
    J Antimicrob Chemother; 2011 Aug; 66(8):1821-30. PubMed ID: 21642652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of bleeding and antibiotic use in patients receiving continuous phenprocoumon therapy. A case-control study nested in a large insurance- and population-based German cohort.
    Abbas S; Ihle P; Harder S; Schubert I
    Thromb Haemost; 2014 May; 111(5):912-22. PubMed ID: 24429904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study.
    Etminan M; Brophy JM; Samii A
    Neurology; 2014 Sep; 83(14):1261-3. PubMed ID: 25150290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.